Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 8/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.49 |
| ▸ | EGFR | P00533 | 11/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17683290 | 0.88 | MAPK8 (0.46) | MAPK8MAPK9MAPK10EGFR | |
| SCHEMBL30459962 | 0.86 | MAPK8 (0.46) | MAPK8MAPK9MAPK10EGFRHRH3 | |
| SCHEMBL19254457 | 0.85 | EGFR (0.48) | MAPK8MAPK9MAPK10EGFRHRH3 | |
| SCHEMBL17683033 | 0.85 | EGFR (0.63) | EGFRHRH3 | |
| SCHEMBL30459749 | 0.85 | EGFR (0.43) | EGFR | |
| SCHEMBL19210259 | 0.85 | EGFR (0.43) | EGFR | |
| SCHEMBL29464139 | 0.83 | EGFR (0.46) | MAPK8MAPK9MAPK10EGFRHRH3 | |
| SCHEMBL29464100 | 0.82 | EGFR (0.45) | MAPK8MAPK9MAPK10EGFRHRH3 | |
| SCHEMBL17683306 | 0.81 | EGFR (0.42) | EGFR | |
| SCHEMBL30459747 | 0.80 | EGFR (0.50) | EGFRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3205650-B1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-10-01 | — | — | US | disclosed |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2019-04-04 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3205650-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016054987-A1 | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313714-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | MAPK8 61/4885MAPK9 27/4885MAPK10 825/4885 |
| US-20190100528-A1 | EGFR INHIBITOR, PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | MAPK8 70/4885MAPK9 33/4885MAPK10 871/4885 |
| US-10428081-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | MAPK8 70/4885MAPK9 33/4885MAPK10 871/4885 |
| US-10259820-B2 | EGFR inhibitor, preparation method and use thereof | EGFR, ERBB2, ERBB4 | MAPK8 61/4885MAPK9 27/4885MAPK10 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.